Trial · NCT00452530
Adverse events222
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 222
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 73 | 1,501 | |
| other | Constipation | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 77 | 1,508 | |
| other | Vomiting | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 77 | 1,501 | |
| other | Vomiting | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 88 | 1,508 | |
| other | Nausea | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 102 | 1,501 | |
| other | Nausea | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 120 | 1,508 | |
| other | Deep vein thrombosis | Vascular disorders | Apixiban, 2.5 mg BID Plus Placebo | 92 | 1,501 | |
| other | Deep vein thrombosis | Vascular disorders | Enoxaparin, 40 mg QD Plus Placebo | 130 | 1,508 | |
| serious | Creatinine renal clearance decreased | Investigations | Apixiban, 2.5 mg BID Plus Placebo | 0 | 1,501 | |
| serious | Creatinine renal clearance decreased | Investigations | Enoxaparin, 40 mg QD Plus Placebo | 1 | 1,508 | |
| serious | Duodenal ulcer | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 1 | 1,501 | |
| serious | Duodenal ulcer | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 0 | 1,508 | |
| serious | Fistula | Musculoskeletal and connective tissue disorders | Apixiban, 2.5 mg BID Plus Placebo | 1 | 1,501 | |
| serious | Fistula | Musculoskeletal and connective tissue disorders | Enoxaparin, 40 mg QD Plus Placebo | 0 | 1,508 | |
| serious | Gastrointestinal haemorrhage | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 0 | 1,501 | |
| serious | Gastrointestinal haemorrhage | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 1 | 1,508 | |
| serious | Hypokinesia | Nervous system disorders | Apixiban, 2.5 mg BID Plus Placebo | 0 | 1,501 | |
| serious | Hypokinesia | Nervous system disorders | Enoxaparin, 40 mg QD Plus Placebo | 1 | 1,508 | |
| serious | Ileus paralytic | Gastrointestinal disorders | Apixiban, 2.5 mg BID Plus Placebo | 0 | 1,501 | |
| serious | Ileus paralytic | Gastrointestinal disorders | Enoxaparin, 40 mg QD Plus Placebo | 1 | 1,508 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00452530/events